LongeVC Portfolio Company Longenesis Partners with Novartis Baltics

Cardiovascular diseases remain the leading cause of mortality in Europe. While many biotechs are focused on prevention, it’s equally critical to address the risks faced by millions of patients today.

Our portfolio company, Longenesis, is piloting an innovative program in Latvia to reduce the risk of heart failure and improve patient outcomes. The program is in collaboration with Novartis Baltics and one of Latvia’s leading hospitals.

• Latvia’s cardiovascular disease incidence reflects Europe’s overall trends, making this pilot a model for broader implementation.
• Longenesis’ digital registry simplifies tracking heart failure and dyslipidemia patients, helping doctors administer timely treatments.
• Their platform integrates data sources into a single dashboard while ensuring privacy and security, addressing a key challenge in healthcare data management.

Congratulations to the Longenesis team for this impactful initiative. To learn more, visit the Longenesis website here.